Clinical Trials Logo

EGFR Exon 20 Mutation clinical trials

View clinical trials related to EGFR Exon 20 Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT05241873 Active, not recruiting - Neoplasms Clinical Trials

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Start date: March 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.

NCT ID: NCT04036682 Recruiting - Clinical trials for Non Small Cell Lung Cancer

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

REZILIENT1
Start date: October 31, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.

NCT ID: NCT03066206 Active, not recruiting - Clinical trials for Recurrent Lung Non-Small Cell Carcinoma

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Start date: March 17, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth..